Evaxion has appointed Dr Helen Tayton-Martin as new Chief Executive Officer, CEO. She will take up her new position on November 24, 2025, and simultaneously step down from Evaxion’s Board of Directors. Prior to Adaptimmune, Dr. Tayton Martin spent 15 years working within the pharma, biotech and consulting environments for various companies. She also previously served as a non-executive director of Trillium Therapeutics from October 2017 through to the sale of the company in November 2021.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Biotech price target raised to $11 from $6 at Lake Street
- Buy Recommendation for Evaxion Biotech Amid Promising Phase 2 Study Results and Future Potential
- Evaxion Biotech trading resumes
- Evaxion Biotech trading halted, volatility trading pause
- Evaxion Biotech Expands Capital Through ADS Sales and Warrant Exercises